Zachary Bessette

GU Oncology Now

High testosterone levels measured by a liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay may predict response to castration for patients with metastatic hormone-sensitive prostate cancer (mHSPC), according to a new study published in <a href="https://www.sciencedirect.com/science/article/abs/pii/S0009898122013948" target="_blank" rel="noopener">Clinica Chimica Acta</a>.Prior research has shown that testosterone levels are linked with progression-free survival (PFS) in patients with mHSPC. However, this association has primarily been investigated by inaccurate immunoassays.Researchers from the Netherlands examined whether castrate testosterone levels determined by LC-MS/MS can be an independent risk factor for treatment response in mHSPC. A total of 106 patients treated with luteinizing hormone-releasing hormone agonists from March 2018 to August 2021 were included in the analysis.In a separate analysis involving 67 of the patients, results from a commonly applied immunoassay were compared with results from LC-MS/MS.Researchers reported that median PFS was shorter for high testosterone levels (&gt;0.231 nmol/L; 18.4 vs 42.6 months; hazard ratio, 1.7; P=.018). Additionally, they found that low testosterone levels and a prostate-specific antigen response below 4 ng/mL were associated with the longest median PFS (46.2 months) compared with any other combination.In the separate analysis, testosterone levels below the median remained associated with longer PFS in LC-MS/MS results, but immunoassay results did not show a similar difference.Study authors wrote that these results indicate &ldquo;high castration testosterone levels measured by LC-MS/MS is an independent response predictor for mHSPC patients.&rdquo;

Serum Testosterone-Measuring Assay Predicts Response to Castration in mHSPC

mCSPC

High testosterone levels measured by a liquid chromatography-tandem mass spectrometry assay may predict response to castration for patients with mHSCP.

Testosterone Assay Predicts mHSPC Castration Response

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe